Nucleotide Metabolism

Learning Objectives

• Describe the structure of a nucleotide and distinguish purines from pyrimidines
• Explain the de novo synthesis pathways for purines and pyrimidines, including the key committed enzymes
• Explain how salvage pathways recycle bases and why they matter clinically
• Trace purine degradation to uric acid and pyrimidine degradation to beta-alanine and beta-aminoisobutyrate
• Connect enzyme defects in nucleotide metabolism (HGPRT, ADA, xanthine oxidase, PRPP synthetase) to their clinical syndromes
• Explain the biochemical basis of gout, Lesch-Nyhan syndrome, and SCID, and how drugs like allopurinol and hydroxyurea exploit these pathways

Quick Answer

Nucleotide metabolism covers how cells build and break down the purine (adenine, guanine) and pyrimidine (cytosine, thymine, uracil) bases that make up DNA and RNA. Cells make nucleotides two ways: de novo synthesis (building the ring from amino acids, CO2, and one-carbon units, mostly in the liver) and salvage (reattaching a free base to PRPP, which is cheaper and happens in nearly every cell). Purines are degraded all the way to uric acid, a poorly soluble compound that crystallizes in joints as gout when it accumulates. Pyrimidines are degraded to soluble, easily excreted products (beta-alanine, beta-aminoisobutyrate, CO2, NH3), so pyrimidine excess never causes a gout-like disease. This pathway matters clinically because it explains gout, tumor lysis syndrome, Lesch-Nyhan syndrome, SCID, and why drugs like allopurinol, 6-mercaptopurine, and methotrexate work the way they do.

Nucleotide Structure and Classification

A nucleotide has three parts: a nitrogenous base, a pentose sugar (ribose in RNA, deoxyribose in DNA), and one to three phosphate groups. Drop the phosphate and you have a nucleoside (base + sugar only) — this distinction matters because many drugs (acyclovir, zidovudine) are nucleoside analogs that need to be phosphorylated inside the cell to become active.

The bases split into two chemical families:

• Purines — adenine (A) and guanine (G) — have a fused double-ring structure (a six-membered ring fused to a five-membered ring).
• Pyrimidines — cytosine (C), thymine (T), and uracil (U) — have a single six-membered ring.

This structural difference is exactly why their degradation products differ so much: purines break down to a ring-shaped, poorly soluble compound (uric acid), while pyrimidines break their ring apart completely into small, water-soluble fragments.

Purine Synthesis: De Novo Pathway

Purine synthesis is unusual because the ring is built directly on the sugar-phosphate backbone — there is no free purine base intermediate. The pathway starts with ribose-5-phosphate (from the pentose phosphate pathway) and builds the purine ring atom by atom using glycine, aspartate, glutamine, CO2, and two one-carbon units donated by N10-formyl-tetrahydrofolate.

Step-by-step logic (you do not need to memorize every enzyme, but know the committed step):

1. PRPP synthetase converts ribose-5-phosphate + ATP into PRPP (5-phosphoribosyl-1-pyrophosphate). PRPP is the shared starting material for both de novo purine synthesis and the salvage pathway — this is why PRPP synthetase overactivity causes gout even before any base is attached.
2. Glutamine-PRPP amidotransferase (also called amidophosphoribosyltransferase) attaches an amine group from glutamine to PRPP, forming 5-phosphoribosylamine. This is the committed, rate-limiting step of de novo purine synthesis, and it is allosterically inhibited by the end products AMP, GMP, and IMP (feedback inhibition).
3. A series of additional enzymatic steps build the full purine ring on the ribose-phosphate, producing inosine monophosphate (IMP) — the first complete purine nucleotide, and the branch point for both AMP and GMP.
4. IMP is converted to AMP (via adenylosuccinate, using GTP as the energy source) or to GMP (via xanthosine monophosphate/XMP, using ATP as the energy source, catalyzed by IMP dehydrogenase). This reciprocal use of GTP to make AMP and ATP to make GMP balances the pools of the two purine nucleotides.

De novo purine synthesis is energetically expensive — it costs roughly 6 ATP equivalents per purine nucleotide — which is exactly why the salvage pathway exists as a shortcut.

Pyrimidine Synthesis: De Novo Pathway

Pyrimidine synthesis works in the opposite order from purine synthesis: the ring is built first as a free base, and the ribose-phosphate is attached afterward.

1. Carbamoyl phosphate synthetase II (CPS-II), a cytosolic enzyme, combines glutamine, CO2, and ATP to form carbamoyl phosphate. (Do not confuse this with CPS-I, the mitochondrial enzyme of the urea cycle — same reaction chemistry, different compartment, different nitrogen source, different purpose.)
2. Carbamoyl phosphate combines with aspartate (via aspartate transcarbamoylase) and cyclizes to form the pyrimidine ring, ultimately producing orotic acid.
3. Orotic acid is then attached to PRPP by orotate phosphoribosyltransferase, forming orotidine monophosphate (OMP), which is decarboxylated by OMP decarboxylase to form uridine monophosphate (UMP) — the parent pyrimidine nucleotide.
4. UMP is phosphorylated to UTP, and UTP is aminated (using glutamine) to form CTP.
5. Thymidylate (dTMP) is made separately, from dUMP, by thymidylate synthase, which uses N5,N10-methylene-tetrahydrofolate as the methyl donor. This single reaction is the pharmacologic target of 5-fluorouracil, and the folate-regenerating enzyme downstream of it, dihydrofolate reductase, is the target of methotrexate — which is why both drugs block DNA synthesis in rapidly dividing cells (cancer, but also gut mucosa and bone marrow, explaining their toxicity profile).

Salvage Pathways

Most cells do not build nucleotides from scratch every time — they recycle bases released from normal nucleic acid turnover. Salvage is far cheaper (1 ATP-equivalent versus roughly 6) and is the dominant source of nucleotides in tissues with high turnover but limited de novo capacity, such as red blood cells and — critically — the brain.

• HGPRT (hypoxanthine-guanine phosphoribosyltransferase) attaches PRPP to hypoxanthine or guanine to regenerate IMP or GMP. This enzyme is the star of Lesch-Nyhan syndrome (see below) because neurons rely almost entirely on salvage and cannot compensate when HGPRT is absent.
• APRT (adenine phosphoribosyltransferase) attaches PRPP to adenine to regenerate AMP.
• Pyrimidine bases are salvaged too (via pyrimidine phosphoribosyltransferase), though this pathway is less clinically emphasized than the purine salvage enzymes.

Because both de novo synthesis and salvage draw on the same PRPP pool, anything that increases PRPP availability (like PRPP synthetase overactivity) or blocks salvage (like HGPRT deficiency, which leaves more PRPP and hypoxanthine available for de novo synthesis) pushes more flux through de novo purine synthesis and raises uric acid production.

Nucleotide Degradation

Purine Catabolism

All purines, regardless of whether they came from AMP or GMP, converge on a common degradation route:

AMP/GMP → (via inosine/guanosine and hypoxanthine/guanine intermediates) → xanthine → uric acid

The key enzyme is xanthine oxidase, which catalyzes two oxidation steps: hypoxanthine → xanthine, and xanthine → uric acid. Uric acid is the final excretion product in humans because we lack a functional uricase enzyme (unlike most other mammals, which convert uric acid further to the more soluble allantoin). This evolutionary loss is exactly why humans — uniquely among most mammals — are prone to gout.

Pyrimidine Catabolism

Pyrimidines are degraded completely, opening and dismantling the ring rather than leaving it intact:

• Cytosine and uracil → beta-alanine + CO2 + NH3
• Thymine → beta-aminoisobutyrate + CO2 + NH3

Both end products are small, water-soluble molecules that are easily excreted or further metabolized (beta-alanine can feed into other pathways). Because nothing insoluble accumulates, there is no pyrimidine equivalent of gout.

Concept Flow: Purine and Pyrimidine Metabolism Overview

Clinical Significance

• Gout: Hyperuricemia (uric acid overproduction or, more commonly, underexcretion by the kidney) leads to monosodium urate crystal deposition in joints, causing acute inflammatory arthritis — classically the first metatarsophalangeal joint (podagra). Chronic disease produces tophi. First-line treatment for acute attacks is NSAIDs or colchicine; allopurinol (a hypoxanthine analog that inhibits xanthine oxidase) is used for chronic prevention by lowering uric acid production.
• Lesch-Nyhan syndrome: X-linked complete deficiency of HGPRT. Without salvage, hypoxanthine and guanine cannot be recycled, so more PRPP and base remain available to drive de novo purine synthesis, causing severe hyperuricemia and gout in childhood. The neurologic triad — intellectual disability, dystonia/choreoathetosis, and compulsive self-mutilation (lip and finger biting) — reflects the brain's dependence on purine salvage, since neurons have low de novo synthesis capacity.
• Severe combined immunodeficiency (SCID): Adenosine deaminase (ADA) deficiency causes accumulation of deoxyadenosine and dATP, which is toxic to lymphocytes (it inhibits ribonucleotide reductase, starving cells of the other dNTPs needed for replication). This selectively kills developing T and B cells, producing one of the classic causes of SCID.
• Tumor lysis syndrome: Rapid killing of tumor cells (typically after starting chemotherapy for high-turnover cancers like leukemia/lymphoma) releases massive amounts of nucleic acid, which is degraded to uric acid faster than the kidneys can excrete it, causing acute uric acid nephropathy and hyperkalemia. Prevention uses aggressive hydration plus allopurinol or rasburicase (recombinant uricase, which restores the enzyme humans lack).
• Orotic aciduria: Deficiency of UMP synthase (the enzyme combining orotate phosphoribosyltransferase and OMP decarboxylase activities) causes orotic acid to accumulate, presenting with megaloblastic anemia that does NOT improve with B12 or folate, plus failure to thrive and orotic acid crystals in the urine. It is treated by giving oral uridine, which bypasses the block and also suppresses CPS-II via feedback inhibition, lowering orotate production.

Key Terms

Term	Definition	Related Concept
Purine	Fused double-ring nitrogenous base (adenine, guanine)	De novo synthesis, xanthine oxidase, gout
Pyrimidine	Single-ring nitrogenous base (cytosine, thymine, uracil)	Orotic acid, thymidylate synthase
PRPP	5-phosphoribosyl-1-pyrophosphate; the activated ribose-phosphate donor shared by de novo and salvage pathways	PRPP synthetase, HGPRT, APRT
De novo synthesis	Building nucleotides from amino acids, CO2, and one-carbon units rather than recycling bases	Committed step, feedback inhibition
Salvage pathway	Recycling free bases back into nucleotides using PRPP, at lower energy cost than de novo synthesis	HGPRT, APRT, Lesch-Nyhan syndrome
HGPRT	Hypoxanthine-guanine phosphoribosyltransferase; salvages hypoxanthine and guanine	Lesch-Nyhan syndrome, X-linked
Xanthine oxidase	Enzyme converting hypoxanthine to xanthine and xanthine to uric acid	Allopurinol, gout
Uric acid	Final, poorly soluble product of purine degradation in humans	Gout, tumor lysis syndrome
Adenosine deaminase (ADA)	Converts adenosine to inosine; deficiency causes toxic dATP buildup in lymphocytes	SCID
Orotic acid	Intermediate of pyrimidine synthesis; accumulates in orotic aciduria and OTC deficiency	UMP synthase, urea cycle
Thymidylate synthase	Converts dUMP to dTMP using a folate-derived methyl group	5-fluorouracil, methotrexate

Common Mistakes

Misconception: Purines and pyrimidines are degraded the same way, so both can cause gout. Why it's wrong: Purine catabolism ends in uric acid, a ring-shaped compound with low water solubility that crystallizes at physiologic pH and temperature in cooler peripheral joints. Pyrimidine catabolism opens and completely dismantles the ring into small, soluble fragments (beta-alanine, beta-aminoisobutyrate) that never accumulate to crystallize. Correct understanding: Only purine excess causes gout. There is no pyrimidine-associated crystal arthropathy — if a question describes gout-like symptoms tied to a metabolic pathway, the answer is always on the purine side.

Misconception: De novo synthesis and salvage are independent, competing pathways for making nucleotides. Why it's wrong: Both pathways consume the same PRPP pool and often the same downstream enzymes converge on IMP/GMP. When salvage fails (as in HGPRT deficiency), the "freed-up" PRPP and unsalvaged bases are shunted into the de novo pathway, increasing — not decreasing — purine synthesis and uric acid production. Correct understanding: The two pathways are linked through shared substrates. Losing salvage capacity paradoxically increases de novo flux and hyperuricemia, which is exactly the mechanism behind Lesch-Nyhan syndrome.

Misconception: Allopurinol works by directly lowering PRPP or blocking purine synthesis. Why it's wrong: Allopurinol is a hypoxanthine analog that inhibits xanthine oxidase, the enzyme that converts hypoxanthine to xanthine and xanthine to uric acid. It acts at the degradation step, not at synthesis. Correct understanding: Allopurinol lowers uric acid by blocking the last two oxidation steps of purine catabolism. A clinically important consequence is that allopurinol slows the breakdown of 6-mercaptopurine and azathioprine (both metabolized by xanthine oxidase), so doses of these immunosuppressants/chemotherapy agents must be reduced when co-administered with allopurinol.

Comparison and Connections

Feature	Purine Synthesis/Degradation	Pyrimidine Synthesis/Degradation
Ring assembly	Built directly on ribose-5-phosphate/PRPP	Free base (orotate) built first, then attached to PRPP
Committed enzyme	Glutamine-PRPP amidotransferase	Carbamoyl phosphate synthetase II (CPS-II)
Nitrogen/carbon sources	Glycine, aspartate, glutamine, CO2, N10-formyl-THF	Glutamine, CO2, aspartate
Key salvage enzyme	HGPRT (and APRT)	Pyrimidine phosphoribosyltransferase (minor clinical role)
Final degradation product	Uric acid (insoluble)	Beta-alanine / beta-aminoisobutyrate (soluble)
Disease of excess	Gout, Lesch-Nyhan syndrome	Not associated with a crystal arthropathy
Disease of deficiency in synthesis	ADA deficiency (SCID)	Orotic aciduria (UMP synthase deficiency)
Key drug target	Xanthine oxidase (allopurinol)	Thymidylate synthase (5-FU), DHFR (methotrexate)

Practice Questions

Recall

1. What are the two purine bases and the three pyrimidine bases? Answer guidance: Purines: adenine and guanine (double-ring structure). Pyrimidines: cytosine, thymine, and uracil (single-ring structure).

2. Which enzyme catalyzes the committed step of de novo purine synthesis, and what regulates it? Answer guidance: Glutamine-PRPP amidotransferase converts PRPP + glutamine to 5-phosphoribosylamine. It is allosterically inhibited by the end products AMP, GMP, and IMP (feedback inhibition), keeping purine synthesis matched to cellular need.

Understanding

3. Explain why humans, unlike most other mammals, are susceptible to gout. Answer guidance: Most mammals possess uricase, which converts uric acid to the more soluble allantoin for easy excretion. Humans lack functional uricase, so uric acid is the terminal purine degradation product; because it is poorly soluble, it can crystallize in joints, especially cooler peripheral ones like the great toe.

4. Why does HGPRT deficiency increase, rather than decrease, purine synthesis? Answer guidance: HGPRT normally salvages hypoxanthine and guanine using PRPP. When HGPRT is absent, both PRPP and the free bases are not consumed by salvage, leaving more PRPP available to drive the de novo pathway, which increases purine synthesis and uric acid production — explaining the severe hyperuricemia in Lesch-Nyhan syndrome.

Application

5. A 55-year-old man with a history of leukemia is started on chemotherapy. Three days later he develops acute kidney injury, hyperkalemia, and joint pain. What is happening biochemically, and how could it have been prevented? Answer guidance: This is tumor lysis syndrome — rapid destruction of leukemic cells releases large amounts of nucleic acids, which are degraded through the purine catabolic pathway to uric acid faster than the kidneys can excrete it, causing acute uric acid nephropathy. Prevention includes aggressive IV hydration and prophylactic allopurinol (blocks xanthine oxidase) or rasburicase (recombinant uricase) before or with chemotherapy initiation.

6. A patient on azathioprine for an autoimmune condition is started on allopurinol for gout. What dosing adjustment is needed and why? Answer guidance: Azathioprine is converted to 6-mercaptopurine, which is normally inactivated by xanthine oxidase. Allopurinol inhibits xanthine oxidase, so co-administration raises active drug levels and risks bone marrow toxicity. The azathioprine (or 6-mercaptopurine) dose must be reduced substantially (typically to about 25-33% of usual) when allopurinol is co-prescribed.

Analysis

7. Compare why purine excess causes a clinical disease (gout) but pyrimidine excess does not produce an analogous crystal arthropathy. Answer guidance: The difference lies in degradation chemistry. Purine catabolism preserves the fused ring structure and ends at uric acid, a compound with low aqueous solubility that precipitates as monosodium urate crystals under physiologic conditions. Pyrimidine catabolism breaks the ring open entirely, yielding small, freely soluble metabolites (beta-alanine, beta-aminoisobutyrate) that are readily excreted without crystallizing.

8. A neonate presents with megaloblastic anemia unresponsive to B12 and folate, along with failure to thrive and orotic acid crystals in the urine, but no hyperammonemia. Contrast this with a patient with ornithine transcarbamoylase (OTC) deficiency, who also has elevated orotic acid. How do you distinguish them biochemically? Answer guidance: Both conditions raise orotic acid, but through opposite mechanisms. In UMP synthase deficiency (orotic aciduria), the pyrimidine synthesis pathway is blocked downstream of orotate formation, so orotate accumulates while pyrimidine nucleotides (needed for DNA synthesis in rapidly dividing bone marrow cells) are deficient, causing megaloblastic anemia; ammonia is normal because the urea cycle is intact. In OTC deficiency (a urea cycle disorder), excess carbamoyl phosphate escapes the mitochondria and is shunted into the (intact) cytosolic pyrimidine pathway, raising orotic acid as a side effect, but the primary problem is failure to detoxify ammonia, so the patient presents with hyperammonemia, not anemia. The presence or absence of hyperammonemia is the key distinguishing clinical clue.

FAQ

1. Do I need to memorize every enzyme name in the purine and pyrimidine pathways? No. Focus on the committed/rate-limiting enzymes (glutamine-PRPP amidotransferase for purines, CPS-II for pyrimidines), the salvage enzymes (HGPRT, APRT), the degradation enzyme (xanthine oxidase), and the enzymes tied to named diseases (ADA, UMP synthase, thymidylate synthase). Exams reward understanding which step is blocked and what happens downstream, not reciting the full 10-step sequence.

2. Why does purine synthesis happen on the ribose-phosphate while pyrimidine synthesis happens on a free base first? This is simply how the two pathways evolved, but it has a testable consequence: purine synthesis has no free purine base intermediate (the ring is built directly onto PRPP), while pyrimidine synthesis produces a free base (orotic acid) that only attaches to PRPP afterward. If a question describes a free base accumulating before ribose attachment, think pyrimidine (orotic aciduria), not purine.

3. Why is allopurinol used for chronic gout but not for an acute gout attack? Allopurinol lowers uric acid production over time by inhibiting xanthine oxidase, but it does not have anti-inflammatory activity and can transiently mobilize existing crystals during initiation, sometimes triggering a flare. Acute attacks are treated with NSAIDs, colchicine, or steroids to control inflammation; allopurinol is started (or continued) between attacks for long-term urate lowering.

4. Is Lesch-Nyhan syndrome the same as ordinary gout? No. Ordinary gout usually reflects a combination of overproduction and (more commonly) underexcretion of uric acid in adults, often with a metabolic syndrome or diuretic-use component. Lesch-Nyhan syndrome is a complete, X-linked HGPRT deficiency presenting in infancy/childhood with severe hyperuricemia, gout, and a distinctive neurobehavioral phenotype (self-mutilation, dystonia, intellectual disability) that ordinary gout never causes.

5. How does this pathway connect to chemotherapy drugs I'll see in pharmacology? Several major chemotherapy classes exploit nucleotide metabolism: methotrexate inhibits dihydrofolate reductase (blocking the folate regeneration needed for thymidylate synthase), 5-fluorouracil directly inhibits thymidylate synthase, 6-mercaptopurine (activated via HGPRT) blocks de novo purine synthesis, and hydroxyurea inhibits ribonucleotide reductase (blocking conversion of ribonucleotides to deoxyribonucleotides). All work by starving rapidly dividing cells of the nucleotides they need to replicate DNA.

Quick Revision

• Nucleotide = base + sugar + phosphate; nucleoside = base + sugar only
• Purines (A, G) have a double ring; pyrimidines (C, T, U) have a single ring
• De novo purine synthesis is built directly on PRPP; committed step is glutamine-PRPP amidotransferase, feedback-inhibited by AMP/GMP/IMP
• De novo pyrimidine synthesis builds orotic acid first (via CPS-II), then attaches PRPP to make UMP
• Salvage pathways (HGPRT for hypoxanthine/guanine, APRT for adenine) recycle bases using PRPP and are far cheaper than de novo synthesis
• Purine degradation converges on uric acid via xanthine oxidase; humans lack uricase, so uric acid is the end product
• Pyrimidine degradation fully dismantles the ring into soluble beta-alanine/beta-aminoisobutyrate — no crystal disease results
• Gout = hyperuricemia from purine overproduction or underexcretion; treat acute attacks with NSAIDs/colchicine, prevent chronically with allopurinol (xanthine oxidase inhibitor)
• Lesch-Nyhan syndrome = X-linked HGPRT deficiency → severe hyperuricemia + self-mutilation, dystonia, intellectual disability
• ADA deficiency → toxic dATP accumulation → kills lymphocytes → SCID
• UMP synthase deficiency = orotic aciduria: high orotic acid, megaloblastic anemia unresponsive to B12/folate, normal ammonia (distinguishes it from OTC deficiency)
• Thymidylate synthase (target of 5-FU) and dihydrofolate reductase (target of methotrexate) are the key drug targets in pyrimidine metabolism

Related Topics

Prerequisites: Introduction to Biochemistry (enzymes, metabolic pathway logic), amino acid structure and the one-carbon/folate pool, basic pentose phosphate pathway (source of ribose-5-phosphate)

Related Topics: Urea cycle (shares carbamoyl phosphate chemistry with pyrimidine synthesis via the related CPS-I/CPS-II enzymes), DNA replication and repair (the end consumer of dNTPs), Pharmacology of antimetabolites (methotrexate, 5-FU, 6-mercaptopurine, hydroxyurea)

Next Topics: Amino Acid Metabolism, Molecular Biology and Genetics, Clinical Biochemistry of inherited metabolic disorders

---

This page is for educational purposes. Always verify with current clinical guidelines.